Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Clinical trials news

Show

From To
NHS England fudges PrEP access and delays on-demand access to PrEP by years; blocks doctors from prescribing PrEP now

It is difficult to be impressed with this compromise. Rather than meet the real need of people currently at highest risk, it will further delay access to an option to prevent HIV transmission that has clearly passed the criteria for safety, efficacy and effectiveness laid out for other NHS treatments.

Published
04 December 2016
From
HIV i-Base
NHS England announces major new PrEP trial for 2017

NHS England, in collaboration with Public Health England, has announced in a press release today that a major new implementation trial of pre-exposure prophylaxis (PrEP) will start

Published
04 December 2016
By
Gus Cairns
Ageing positively: the menopause in women living with HIV

Our team is conducting one of the largest studies to date in Europe, and the first ever in the UK, looking at how the menopause affects the health and wellbeing of women living with HIV.

Published
02 December 2016
From
National Institute for Health Research
Could the FDA be dismantled under Trump?

Has President-elect Donald Trump put a bull’s-eye on the Food and Drug Administration? The agency is facing post-election upheaval. Public health advocates are bracing for a seismic shift: a surrender of the agency’s rules for off-label promotion of drugs; the importation of more drugs from other countries; and fewer requirements for clinical trials.

Published
22 November 2016
From
STAT
DISCOVER Trial Factsheet

Fact sheet explaining the background to the DISCOVER trial

Published
17 November 2016
From
AIDS Foundation of Chicago
Community demand for temporary halt to Gilead DISCOVER study

A group of U.S., Canadian, and European community advocates and HIV NGO workers have written a letter exrpesing "deep dismay" that Gilead Sciences have proceeded with the DISCOVER trial PrEP"without engaging stakeholders in a substantial or meaningful way.". DISCOVER will compared Gilead's new comination pill, Descovy against Truvada as PrEP. In 2007, the HIV/AIDS field adopted Good Participatory Practice (GPP), a formal set of guidelines approved by UNAIDS for stakeholder engagement in HIV prevention clinical trials. "It is astonishing," says the letter, "that Gilead has failed to follow GPP guidelines in the design and implementation of DISCOVER, since GPP was developed partly as a response to the failure of previous prevention trials involving tenofovir."

Published
17 November 2016
From
HIV Prevention Justice Alliance
Why Are HIV Groups Charging Gilead With Bad Behavior in New PrEP Trial?

Gilead is not following the accepted standard for community engagement in its new pre-exposure prophylaxis (PrEP) trial, and we are among a coalition of HIV activists and organizations from Europe and North America calling them out on their bad corporate behavior. We root our criticism in the Good Participatory Practice (GPP) guidelines that were inspired, in part, by controversies in earlier PrEP trials.

Published
17 November 2016
From
The Body
Statement on DISCOVER Study of F/TAF for PrEP

Gilead Sciences released this statement after considerable interest and concerns abut the forthcoming study of their new tenofovir formulation, TAF, for use in PrEP. The TAF/FTC pill is called Descovy(R). "Gilead Sciences is sponsoring a clinical trial, known as the DISCOVER study, to test whether a combination of emtricitabine and tenofovir alafenamide (F/TAF) is as safe and effective as Truvada® (emtricitabine and tenofovir disoproxil fumarate, F/TDF) at reducing the risk of HIV infection when used as pre-exposure prophylaxis (PrEP). F/TAF was recently approved for HIV treatment, but it is not yet known whether it is effective as PrEP...."

Published
16 November 2016
From
Gilead Sciences
Huge diversity in current HIV vaccine research, Research for Prevention conference hears

The HIV vaccine research field is currently going through probably its most fertile and diverse period yet, the second HIV Research for Prevention conference (HIVR4P) in Chicago

Published
23 October 2016
By
Gus Cairns
My transition toward trans awareness

I recall when a colleague told me in 2014 that some transgender women advocates were unhappy with iPrEx. I was surprised and disappointed.

Published
08 September 2016
From
Robert Grant (blog)
← First12345...18Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.